Anbio Biotechnology (NNNN) Non-Current Assets (2023 - 2024)
Anbio Biotechnology (NNNN) recorded quarterly Non-Current Assets of $387440.0 in Q4 2024, up 523.53% quarter-over-quarter from $62137.0 in Q4 2023, and up 523.53% on a YoY basis from $62137.0 in Q1 2024.
Anbio Biotechnology (NNNN) Non-Current Assets (2023 - 2024) Analysis & Trends
Anbio Biotechnology's Non-Current Assets history runs 2 years deep, the most recent figure standing at $387440.0 for Q4 2024.
- In Q4 2024, Non-Current Assets rose 523.53% year-over-year to $387440.0; the TTM figure through Dec 2025 stood at $449577.0 (changed N/A YoY), while the FY2024 annual figure was $387440.0, up 523.53% from the prior year.
- Non-Current Assets was $387440.0 for Q4 2024 at Anbio Biotechnology, up from $62137.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $387440.0 in Q4 2024 to a low of $62137.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 11.30 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 42.82 Bn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 27.83 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 4.72 Bn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 2.28 Bn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 10.51 Bn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 10.18 Bn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 3.66 Bn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 13.00 Bn |
| 10 | Anbio Biotechnology | 720.59 Mn | 708.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 387,440.00 |
| Dec 31, 2023 | 62,137.00 |